Shares of Eli Lilly & Co. LLY sank 0.19% to $794.14 Thursday, on what proved to be an all-around mixed trading session for ...

Eli Lilly has ... trials front Lilly announced plans to start a five-year real-world evidence study involving tirzepatide, the dual GIP/GLP-1 receptor agonist in the company's Mounjaro drug ...